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A case-control study of sporadic Creutzfeldt-Jakob disease in
Switzerland: analysis of potential risk factors with regard to an
increased CJD incidence in the years 2001-2004
Abstract
BACKGROUND: In 2001, the observed annual mortality from Creutzfeldt-Jakob disease (CJD) in
Switzerland increased from less than 1.5 to 2.6 per million inhabitants. An underlying cause could not
be identified. METHODS: To analyse potential risk factors for sCJD in Switzerland, close relatives of
69 sCJD-patients and 224 frequency age-matched controls were interviewed in a case-control study
using a standardised questionnaire. 135 potential risk factors including socio-demographics, medical
history, occupation and diet were analysed by logistic regression adjusting for age, sex and education.
RESULTS: sCJD patients were more likely to have travelled abroad, worked at an animal laboratory,
undergone invasive dental treatment, orthopaedic surgery, ophthalmologic surgery after 1980, regular
GP visits, taken medication regularly, and consumed kidney. No differences between patients and
controls were found for residency, family history, and exposure to environmental and other dietary
factors. CONCLUSION: Although some factors were significantly more frequent among sCJD-cases,
this study did not reveal specific explanations for the increased incidence of deaths due to sporadic CJD
observed in Switzerland since 2001. Results have to be interpreted with caution due to multiple testing
and possible recall bias in association with a long incubation period. The most plausible reason for the
increase in Swiss sCJD cases after 2000 is an improved case ascertainment. Therefore, underreporting of
cases might well have occurred before the year 2001, and the "real" yearly incidence of sCJD might not
be lower than, but rather above 2 per million inhabitants.
BioMed CentralBMC Public Health
ssOpen AcceResearch article
A case-control study of sporadic Creutzfeldt-Jakob disease in 
Switzerland: analysis of potential risk factors with regard to an 
increased CJD incidence in the years 2001–2004
Jessica Ruegger†1, Katharina Stoeck†2,3, Lorenz Amsler4,5, Thomas Blaettler2,6, 
Marcel Zwahlen7, Adriano Aguzzi2, Markus Glatzel2,8, Klaus Hess1 and 
Tobias Eckert*4,9
Address: 1Department of Neurology, University Hospital Zurich, Zurich, Switzerland, 2Institute of Neuropathology, University Hospital Zurich, 
Zurich, Switzerland, 3Department of Neurology, University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Hamburg, Germany, 4Federal 
Office of Public Health, Bern, Switzerland, 5CSL Behring, Bern, Switzerland, 6Bristol-Myers Squibb, Wallingford, CT, USA, 7Institute of Social and 
Preventive Medicine, University of Bern, Bern, Switzerland, 8Institute of Neuropathology, University Hospital Hamburg-Eppendorf, Hamburg-
Eppendorf, Hamburg, Germany and 9Swiss Tropical Institute, Basel, Switzerland
Email: Jessica Ruegger - jessica.ruegger@gmail.com; Katharina Stoeck - kstoeck@uke.uni-hamburg.de; 
Lorenz Amsler - Lorenz.Amsler@cslbehring.com; Thomas Blaettler - thomas.blaettler@bms.com; Marcel Zwahlen - zwahlen@ispm.unibe.ch; 
Adriano Aguzzi - adriano.aguzzi@usz.ch; Markus Glatzel - m.glatzel@uke.uni-hamburg.de; Klaus Hess - k_h@bluewin.ch; 
Tobias Eckert* - tobias.eckert@bag.admin.ch
* Corresponding author    †Equal contributors
Abstract
Background: In 2001, the observed annual mortality from Creutzfeldt-Jakob disease (CJD) in Switzerland
increased from less than 1.5 to 2.6 per million inhabitants. An underlying cause could not be identified.
Methods: To analyse potential risk factors for sCJD in Switzerland, close relatives of 69 sCJD-patients
and 224 frequency age-matched controls were interviewed in a case-control study using a standardised
questionnaire. 135 potential risk factors including socio-demographics, medical history, occupation and
diet were analysed by logistic regression adjusting for age, sex and education.
Results: sCJD patients were more likely to have travelled abroad, worked at an animal laboratory,
undergone invasive dental treatment, orthopaedic surgery, ophthalmologic surgery after 1980, regular GP
visits, taken medication regularly, and consumed kidney. No differences between patients and controls
were found for residency, family history, and exposure to environmental and other dietary factors.
Conclusion: Although some factors were significantly more frequent among sCJD-cases, this study did
not reveal specific explanations for the increased incidence of deaths due to sporadic CJD observed in
Switzerland since 2001. Results have to be interpreted with caution due to multiple testing and possible
recall bias in association with a long incubation period. The most plausible reason for the increase in Swiss
sCJD cases after 2000 is an improved case ascertainment. Therefore, underreporting of cases might well
have occurred before the year 2001, and the "real" yearly incidence of sCJD might not be lower than, but
rather above 2 per million inhabitants.
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Creutzfeldt-Jakob disease (CJD) is a rare but inevitably
fatal neurological disorder. CJD is associated with spong-
iform changes in the brain and an accumulation of a mis-
folded protein termed prion, which is believed to be the
agent responsible for transmission of the disease.[1] In
most industrialised countries, CJD is recorded with a
yearly incidence of 1.0–1.5 cases per million inhabit-
ants.[2] There are several pathogenically distinct forms of
CJD, of which the classical forms (sporadic, genetic and
iatrogenic) have been known for decades. Another form,
variant CJD (vCJD), was first described in the United
Kingdom in 1996, and consensus exists that vCJD is
caused by ingestion of bovine products, particularly of so-
called "risk material" from cattle infected with Bovine
spongiform encephalopathy (BSE).[3,4] Among the three
classical forms, genetic CJD (gCJD) develops due to spe-
cific mutations in the prion gene, while iatrogenic CJD
(iCJD) has resulted from contaminated blood, human pit-
uary gland hormone products, dura mater and corneal
grafts, and during neurosurgery via surgical instruments
and stereotactic EEG electrodes from one patient to
another. [5-11] However, after the implementation of pre-
ventive measures such as more efficient sterilisation pro-
cedures and prohibiting the use of human dura mater,
iatrogenic cases were observed less frequently.[12] Spo-
radic CJD (sCJD) is by far the most common of all CJD
forms, accounting for 80 to 90% of all cases.[13] Its aeti-
ology remains unknown.[14]
In Switzerland, mandatory reporting of definite CJD cases
was introduced in 1987, and since 1999 all clinically sus-
pected CJD cases must be reported as well. In the year
2001, the annual mortality rate increased significantly to
2.6 per million inhabitants from around 1.4 per million
observed during the 1990ies.[15] Figure 1 shows yearly
incidences of reported CJD deaths in Switzerland:
between 1988 and 2000, an average of 9 definite and
probable CJD deaths according to European criteria (max-
imum: 11 cases in 2000) were reported annually.[16] In
2001, 19 deaths were reported, an increasing trend that
was sustained in the following years with 18 deaths in
2002, 17 in 2003, 16 in 2004, 10 in 2005, 13 in 2006 and
15 deaths in 2007. This increase in reported CJD-deaths
was observed in all parts of the country and without any
indications for a geographical change. All deaths in the
Reported deaths from "classical forms" of definite and probable CJD (i.e. sporadic, familial and iatrogenic) in Switzerland (1990–2007)Figu e 1
Reported deaths from "classical forms" of definite and probable CJD (i.e. sporadic, familial and iatrogenic) in 
Switzerland (1990–2007).
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and until November 2008, no case of vCJD has been
recorded in Switzerland.[17]
A comparable increase in CJD-cases has not been
observed in Switzerland's neighbouring countries (Aus-
tria, Germany, France and Italy). Corresponding figures
are available on the website of The European and Allied
Countries Collaborative Study Group of CJD
(EUROCJD).[16] The reason for this sudden rise in the
annual death rate for CJD in 2001 in Switzerland was
unclear, and was therefore investigated in a case-control
study. Three main hypotheses have been discussed: the
observed increase could have been caused by a) a
zoonotic cause similar to the transmission of BSE in
patients with vCJD, b) an iatrogenic cause or c) ascertain-
ment bias due to a heightened perception and awareness
level of the disease in physicians.[18,19] The two former
hypotheses would refer to a so far unknown route of
transmission for sporadic CJD, since the sCJD cases
included in this study did not show any of the character-
istic pathological findings of vCJD. Furthermore, they
have not been exposed to any of the known iatrogenic risk
factors like cadaveric derived pituary hormones or dura
mater grafts. Blood transfusion has been shown to be a
potential route of vCJD transmission and could therefore
be a potential risk factor for other forms of CJD.[11,20] As
far as the BSE epidemic in cattle is concerned, Switzerland
was among the countries in Europe experiencing an early
and high rise in BSE cases, even if the incidence remained
significantly below that observed in the United King-
dom.[21] Therefore, with rising case numbers of vCJD in
the United Kingdom, the question arose if the "surplus" of
sporadic cases in Switzerland could be related to dietary
risk factors in analogy to the development of vCJD.
The principal aim of this study was to investigate whether
there are specific exposures that could explain the rise in
mortality rates for sCJD observed in Switzerland in the
years 2001–2004. A focus was set on external and thus
preventable risk factors.
Methods
Case-patients
All cases included in this study were sCJD patients with
residence in Switzerland recorded by the mandatory Swiss
infectious disease notification system between January
2001 and December 2004 (n = 72). Surveillance of CJD is
carried out by the Swiss Federal Office of Public Health
(SFOP) in collaboration with neurologists, neuropatholo-
gists, psychiatrists, cantonal physicians and the National
Reference Centre for Prion Diseases (NRPE) in Zürich.
During the recruitment time 2001–2004, two genetic CJD
cases as well as one iatrogenic case (due to a dura mater
graft) occurred, which were not included in this study. In
addition, cases were excluded if their relatives and/or phy-
sicians did not consent to the study (n = 3), resulting in 69
patients with sCJD included in the study. Among these 69
cases, diagnosis of CJD was histologically and biochemi-
cally confirmed in 61 patients (88.4%). Eight patients
(11.6%) were classified as probable sCJD cases according
to the criteria of the European Creutzfeldt-Jakob Disease
Surveillance Network EuroCJD.[16] Codon 129 M/V pol-
ymorphism was analysed in all CJD patients where blood
or frozen brain samples were available. PRNP sequencing
was performed in samples where written consent was
given by the patient or close relatives. A description of the
analysis of the genetic markers was published else-
where.[22] The interviewed proxy for patients was either
the spouse, a close relative or in a few instances another
close person such as a friend, who had known the patient
for several years.
Controls
Data of 224 controls were included in this study. To limit
potential selection bias, controls were recruited in two dif-
ferent ways. The first group (n = 69) was recruited from
general practitioner (GP) offices between November 2004
and July 2005. The second group (n = 155) was recruited
by random digit telephone dialling from June to Septem-
ber 2005.
Controls recruited from GP offices were matched by age
and district of residence, and were chosen randomly by
the following procedure: the GP was asked to select from
his collection of patient records in an alphabetic order the
next suitable matching control record following his own
family name. This record was excluded if the age was more
than 5 years different from that of the corresponding con-
trol patient. Potential control subjects were excluded from
participation if they were suffering from a severe disease
or were known to their GP as being a very non-compliant
patient. For each GP, a maximum of three corresponding
controls were included. A standard model letter with an
informed consent enclosed was sent to the matched control
and a face-to-face interview was arranged.
In order to compare cases with the general population, the
second control group (n = 155) was recruited by random
digit telephone dialling based on the Swiss Telephone reg-
istry [Twixtel Version 32 (5/2005)]. These control subjects
were frequency matched by 5-year age group, sex and res-
idency within the same language region of Switzerland.
According to the Swiss Federal Statistical Office (FSO),
71% of the Swiss population was reachable by a fixed line
telephone number in December 2004.
Data collection
For both, cases and controls, a standardised questionnaire
was used, which was translated from English into Ger-
man, French and Italian. This questionnaire had previ-
ously been used in case-control studies in the UnitedPage 3 of 12
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network.[23,24] A total of 135 different items on social
factors, residential history, travel history, family history,
previous medical history (surgery, medical treatments and
drug use), as well as potential environmental (occupa-
tion, animals and farming) and dietary risk factors were
analysed. As an example for previous medical history,
controls and proxy persons for the CJD-patient were asked
if they had ever taken any medications regularly (i.e. for a
period > 1 month) since the beginning of 1980. Respond-
ents were told not to include treatments related to CJD or
their current disease, respectively.
Ethical issues
Data collection of cases is an integral part of the intensi-
fied CJD surveillance in Switzerland which became effec-
tive in November 2002 by a decree of the Federal Council.
The database is registered at the Swiss Federal Data Protec-
tion Commissioner, and the study was approved by the
ethics committee of the Canton of Zurich. All data were
analysed in an anonymous manner.
Statistical methods and analysis
Power calculations for an unmatched case-control study
were performed prior to collecting data on control sub-
jects. The calculations were performed for the total of both
control groups. For 69 cases and 224 controls, assuming a
prevalence for a certain exposure of 25.0% in cases and of
10.0% in controls (resulting in an odds ratio of 2.96), the
study exhibited a power of 80% at the α = 5% confidence
level. Cases were not only compared with all controls
compiled, but also with each of the two control groups in
separate subgroup analyses. The direct matching in the GP
control group, e.g. controls having the same GP as the
cases, was only possible for one third of all patients.
Therefore the data for both control groups was analysed as
an unmatched case-control study.
All potential risk factors were analysed by summary statis-
tics, logistic regression. The latter included univariable
models (= crude estimates) and models including age, sex
and number of school years (= adjusted estimates).
"Number of school years" was chosen as a proxy parame-
ter for education and socio-economic status. Age,
"number of school years" and the "number of surgical
operations" were taken as continuous variables. All other
variables – including frequency of food consumption –
were taken as a binary variable into the models. Main out-
come measures were odds ratios for assessed exposures
with their corresponding 95% confidence intervals and
two-sided p-values. P-values less than 0.05 were consid-
ered significant. As computer program for data collection
and graphics we used Microsoft "Excel 2000". For power
calculations we used "Statcalc" in EpiInfo Version 6. For
data analysis we used "Intercooled STATA" version
8.0.[25]
Results
Recruitment of controls
GP controls
69 general practitioner control subjects were recruited. For
19 of the CJD patients, three corresponding controls were
interviewed, and for another six patients two correspond-
ing controls were interviewed. None of the addressed con-
trol persons declined participation. However, the GP's of
the remaining 44 patients rejected to participate in the
study, and for these patients, no direct control subjects
were interviewed.
Telephone controls
2272 telephone numbers were chosen by random digit
dialling, and a letter informing about the study before-
hand was sent to the corresponding addresses. In house-
holds with valid telephone numbers (n = 2095), the
response rate was 68%, which corresponds to 1422
screened households. In 1035 of these households, no tar-
get person of matching age, sex or residence requirements
could be identified. Among 387 identified target persons,
156 interviews were completed, of which one could not
be used due to missing data. 231 target persons declined
participation. Thus the final response rate of target per-
sons was 40%.
Associations of sporadic CJD with potential risk factors
Socio-demographic, residential and other background factors
Associations of sCJD with age, sex, country of birth, edu-
cation, marital status, and residence in German versus
French and Italian speaking parts of Switzerland are
shown in table 1. Other potential risk factors such as left
versus right handedness, family history of dementia and
travel history are also shown in this table. When adjusted
for age, sex and education, sCJD patients more often trav-
elled abroad (OR 9.31 95% CI (3.63–23.91). Controls on
the other hand had travelled more often to tropical desti-
nations (OR 0.43, 95% CI 0.19–1.00) and to the U.K. (OR
0.29, 95% CI 0.10–0.86), the country experiencing the
highest BSE-incidence after 1980. Also, control subjects
had completed more years of education (OR 0.88, 95% CI
0.80–0.97) than sCJD patients. No differences were found
with respect to age, sex, place of birth and living or a fam-
ily history of dementia.
Environmental factors
Results of cases and controls with respect to occupation,
farming related exposure and pet animals are shown in
table 2. Cases had worked significantly more often in an
animal laboratory (OR 9.6; 95% CI 1.4–64.5). Controls
more often owned a pet rodent (OR 0.32, 95% CI 0.16–
0.66). No differences between sCJD patients and controls
were found with respect to all other work-related factors,
such as occupations in the medical care setting, animal
farming or the meat industry. Likewise there were no dif-
ferences in exposure to leather products, fertilisers con-Page 4 of 12
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stays.
Previous medical history
Exposure of cases and controls to surgery is shown in table
3. Results for other invasive medical procedures such as
lumbar punctures, injections, blood donation, transfu-
sions, regular medication as well as non-invasive medical
risk factors such as allergies, cigarette smoking and illegal
drugs are listed in table 4. sCJD patients significantly more
often had undergone orthopaedic surgery (OR: 4.77; 95%
CI: 2.60–8.83), even if limiting the analysis to those who
had been operated after 1980 (OR: 3.55, 95% CI 1.94–
6.49). Similarly, they were more often exposed to oph-
thalmological surgery after 1980 (OR: 2.7, 95% CI 1.1–
6.5), invasive dental treatment after 1980 (OR 2.63; 95%
Table 1: Sociodemographic factors
comparison with all control subjects
risk factor n
total
mean (SD) or % crude estimate age and sex adjusted 
estimate
age, sex and education 
adjusted estimate
cases
n = 69
controls n = 
224
OR 
(95% CI)
p OR (95% CI) p OR (95% CI) p
age (years) 293 68.7 (9.6) 69.6 (8.2) 0.99 
(0.96–1.02)
0.449 0.99 (0.96–
1.02)1
0.444 0.99 
(0.96–1.02)
0.450
age-group 41 – 59 
years
35 15.9 10.7 15 15 15
age-group 60 – 69 
years
103 33.3 35.7 0.63 
(0.27–1.47)
0.283 0.63 
(0.27–1.47)
0.281 0.61 
(0.25–1.50)
0.282
age-group 70 – 79 
years
112 36.2 38.8 0.63 
(0.27–1.45)
0.277 0.61 
(0.26–1.42)
0.249 0.61 
(0.25–1.49)
0.278
age-group 80 – 85 
years
43 14.5 14.7 0.66 
(0.24–1.81)
0.420 0.68 
(0.25–1.86)
0.452 0.65 
(0.23–1.87)
0.427
sex (male) 293 65.2 57.1 1.41 
(0.81–2.47)
0.234 1.41 (0.80–
2.47)1
0.232 1.70 
(0.93–3.08)
0.080
education: ≥ 10 school 
years
289 44.6 71.4 0.32 
(0.18–0.57)
0.000 0.29 
(0.16–0.52)
0.000 0.29 
(0.16–0.52)
0.000
education: N° of 
school years
289 11.0 (3.6) 12.1 (3.2) 0.90 
(0.82–0.98)
0.021 0.88 
(0.80–0.97)
0.009 0.88 
(0.80–0.97)
0.009
education: ≤ 9 school 
years grouped
100 55.4 28.6 15 15 15
education: 10–12 
school years grouped
79 18.5 29.9 0.32 
(0.15–0.67)
0.002 0.31 
(0.15–0.66)
0.002 0.31 
(0.15–0.66)
0.002
education: ≥ 13 school 
years grouped
100 26.2 41.5 0.32 
(0.17–0.63)
0.001 0.31 
(0.16–0.61)
0.001 0.28 
(0.14–0.55)
0.000
marital status 
(married)
293 79.7 72.8 1.47 
(0.76–2.83)
0.250 1.32 
(0.67–2.61)
0.425 1.32 
(0.65–2.67)
0.445
having a partner 293 79.7 73.7 1.40 
(0.73–2.71)
0.311 1.25 
(0.63–2.28)
0.527 1.24 
(0.61–2.53)
0.551
residence in German 
speaking cantons (vs. 
French & Italian 
speaking)
293 76.8 75.9 1.05 
(0.56–1.99)
0.876 1.08 
(0.56–2.07)
0.822 1.03 
(0.52–2.02)
0.931
country of birth 
(foreign2)
292 13.2 19.2 0.64 
(0.30–1.40)
0.263 0.64 
(0.29–1.38)
0.254 0.69 
(0.31–1.52)
0.355
having lived abroad2 
(> 1980)
289 6.1 4.0 1.53 
(0.46–5.15)
0.489 1.46 
(0.42–5.04)
0.549 1.60 
(0.46–5.74)
0.471
frequent travels abroad
(= once per year, > 
1980)4
119 83.3 35.4 9.13 
(3.80–21.97)
0.000 8.61 
(3.47–21.34)
0.000 9.31 
(3.63–23.91)
0.000
travel history to the 
U.K. (> 1980)
276 7.6 22.4 0.28 
(0.10–0.82)
0.020 0.27 
(0.09–0.79)
0.017 0.29 
(0.10–0.86)
0.026
travel history to 
tropical countries 
(> 1980)
276 15.1 28.3 0.45 
(0.20–1.01)
0.053 0.44 
(0.19–0.99)
0.046 0.43 
(0.19–1.00)
0.045
left-handed3 (vs. right) 290 9.1 10.7 0.83 
(0.33–2.13)
0.704 0.83 
(0.32–2.14)
0.701 0.76 
(0.29–1.98)
0.577
dementia in family 
history
291 19.4 15.6 0.77 
(0.38–1.56)
0.466 0.78 
(0.38–1.59)
0.494 0.64 
(0.30–1.37)
0.252
1) only sex or age adjusted, respectively 2) other than Switzerland 3) including ambidextrous 4) GP controls only 5) reference categoryPage 5 of 12
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95% CI 3.44–11.64) and regular medication (OR 2.3;
95% CI: 1.04–5.10). With respect to a hypothesised iatro-
genic transmission, surgical procedures involving lym-
phoid organs or the central nervous system were not
found to be more frequent in sCJD patients than in the
controls. Appendectomy, gastro-colonoscopy, tonsillec-
tomy, lumbar punctures, donating blood as well as cur-
rent cigarette smoking were observed more frequently in
the controls than in sCJD patients.
Dietary factors
In this analysis, among the 20 food items analysed, only
the age-, sex- and education-adjusted estimate of kidney
consumption showed a significant association with sCJD
(OR: 1.96, 95% CI 1.04–3.68), but this difference was
rather weak. Results are shown in table 5.
Subgroup analysis
Results for most of the factors were similar when analysed
for both control groups separately. Factors with significant
differences between the cases and the composite control
groups also displayed significant differences when cases
were compared to the two control groups separately, as
was the case for number of school years for example,
while on the other hand most factors without such differ-
ences in the combined control-group analysis did not dis-
play significant differences when the two control groups
were analysed separately.
Table 2: Environmental risk factors – occupational exposure, farming related exposure and pets (> 1980)
comparison with all control subjects
risk factor n
total
mean (SD) or % crude estimate age and sex adjusted 
estimate
age, sex and education 
adjusted estimate
cases n = 69 controls n = 
224
OR (95% CI) p OR (95% CI) p OR (95% CI) p
medical 
profession
290 6.0 6.3 0.95 
(0.30–2.98)
0.927 1.21 
(0.36–4.09)
0.764 1.49 
(0.43–5.15)
0.533
animal 
laboratory
290 4.5 0.9 5.18 
(0.82–31.65)
0.075 5.32 
(0.86–33.00)
0.073 9.55 
(1.41–64.49)
0.021
pharmaceutical 
laboratory
290 1.5 0.5 3.36 
(0.21–54.51)
0.393 3.45 
(0.21–56.29)
0.385 3.39 
(0.21–55.20)
0.390
research 
laboratory
290 1.5 2.2 0.66 
(0.08–5.75)
0.707 0.62 
(0.07–5.40)
0.662 0.68 
(0.08–5.99)
0.730
work with 
animals (animal 
care, 
veterinarian)
290 14.9 8.1 2.00 
(0.87–4.57)
0.101 2.06 
(0.89–4.80)
0.092 1.45 
(0.59–3.55)
0.419
work in meat 
industry
290 3.0 3.6 0.83 
(0.17–4.00)
0.813 0.83 
(0.17–4.05)
0.816 0.67 
(0.13–3.33)
0.622
work in catering 
industry
290 6.0 2.2 2.77 
(0.72–10.61)
0.138 3.07 
(0.78–12.05)
0.108 2.81 
(0.70–11.27)
0.144
work with 
animal products 
(e.g. leather)
290 4.5 3.1 1.44 
(0.36–5.75)
0.600 1.43 
(0.36–5.74)
0.616 1.45 
(0.35–5.96)
0.610
farm work or 
stay 
(for > 1 week)
289 10.6 14.4 0.71 
(0.30–1.69)
0.436 0.70 
(0.29–1.68)
0.431 0.62 
(0.25–1.50)
0.287
work with hoof 
or horn
288 15.4 13.0 1.22 
(0.56–2.65)
0.622 1.23 
(0.56–2.69)
0.604 1.12 
(0.49–2.53)
0.794
work with 
bonemeal
287 6.3 8.5 0.72 
(0.23–2.18)
0.557 0.67 
(0.22–2.06)
0.484 0.75 
(0.24–2.33)
0.617
work with dried 
blood
289 3.0 3.6 0.84 
(0.17–4.05)
0.828 0.79 
(0.16–3.85)
0.770 0.75 
(0.15–3.83)
0.733
work with 
fertiliser
289 24.2 22.0 1.14 
(0.60–2.17)
0.698 1.15 
(0.60–2.20)
0.677 1.14 
(0.59–2.22)
0.692
pet cat 289 31.8 46.2 0.54 
(0.30–0.97)
0.040 0.55 
(0.31–0.99)
0.046 0.57 
(0.32–1.04)
0.067
pet dog 289 39.4 30.5 1.48 
(0.84–2.62)
0.177 1.48 
(0.84–2.62)
0.179 1.52 
(0.85–2.72)
0.161
pet rodent 288 16.9 36.8 0.35 
(0.17–0.71)
0.003 0.32 
(0.16–0.66)
0.002 0.32 
(0.16–0.66)
0.002Page 6 of 12
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adjusted analyses, sporadic CJD patients compared to just
the GP controls were more likely to have consumed kid-
ney meat (OR: 3.17; 95% CI 1.27–7.94), hamburgers at
restaurants (OR: 3.26; 95% CI 1. 30–8.21), or ever eaten
game meat or venison (OR: 2.68; 95% CI 1.03–7.02).
Sporadic CJD patients were less likely than the GP con-
trols to have dementia in the family history (OR: 0.271;
95% CI 0.07–0.85), to have had surgical interventions
(OR: 0.811; 95% CI 0.68–0.96) and gastro- or colonos-
copy after 1980 (OR: 0.178; 95% CI 0.06–0.49), to have
received blood transfusions (OR: 0.222; 95% CI 0.07–
0.72), and to own a cat (OR: 0.435; 95% CI 0.20–0.92).
When compared to just the telephone controls, in the
adjusted analyses, sCJD patients were more likely to have
undergone invasive dental treatment (OR: 3.11; 95% CI
1.55–6.25), ophthalmologic surgery performed after
1980 (OR: 18.31; 95% CI 3.65–91.97), have taken medi-
caments regularly (OR: 2.84; 95% CI 1.27–6.32) and to
consume sausages more than once a week (OR: 2.22, 95%
CI 1.18–4.18), and less likely to have travelled to the UK
(OR: 0.256; 95% CI 0.09–0.76) or to tropical countries
Table 3: Medical risk factors – surgery
comparison with all control subjects
Risk factor n
total
mean (SD) or % crude estimate age and sex adjusted 
estimate
age, sex and education 
adjusted estimate
cases n = 69 controls
n = 224
OR (95% CI) p OR (95% CI) p OR (95% CI) p
surgery, ever 292 94.1 95.1 0.83 
(0.25–2.68)
0.751 0.94 
(0.28–3.13)
0.921 0.99 (0.29–3.37) 0.984
number of 
operations
292 3.04 (1.71) 4.33 (2.76) 0.93 
(0.81–1.06)
0.260 0.94 
(0.82–1.08)
0.377 0.94 (0.82–1.09) 0.410
neurological 
surgery
289 10.8 7.6 1.47 
(0.58–3.71)
0.416 1.51 
(0.59–3.82)
0.388 1.24 (0.46–3.33) 0.672
neurological 
surgery (> 1980)
289 4.6 1.8 2.66 
(0.58–12.21)
0.208 2.92 
(0.63–13.60)
0.173 2.26 
(0.39–13.04)
0.362
ophthalmological 
surgery
289 15.4 20.5 0.70 
(0.33–1.49)
0.357 0.72 
(0.33–1.59)
0.417 0.79 (0.35–1.78) 0.574
ophthalmological 
surgery (> 1980)
289 15.4 8.5 1.96 
(0.86–4.46)
0.108 2.23 
(0.94–5.28)
0.068 2.67 (1.10–6.49) 0.030
abdominal 
surgery
288 35.9 50.5 0.55 
(0.31–0.98)
0.042 0.56 
(0.31–1.01)
0.054 0.53 (0.29–0.98) 0.041
abdominal 
surgery (> 1980)
288 25.0 18.8 1.44 
(0.75–2.79)
0.273 1.49 
(0.77–2.88)
0.241 1.44 (0.72–2.85) 0.300
appendectomy 292 22.1 37.5 0.47 
(0.25–0.89)
0.020 0.49 
(0.26–0.94)
0.032 0.55 (0.28–1.05) 0.071
appendectomy 
(> 1980)
292 4.4 22.7 0.16 
(0.05–0.52)
0.002 0.16 
(0.05–0.54)
0.003 0.16 (0.05–0.55) 0.003
gastro- or 
colonoscopy
285 24.6 44.2 0.41 
(0.22–0.78)
0.007 0.43 
(0.22–0.81)
0.010 0.45 (0.23–0.87) 0.017
gastro-/
colonoscopy 
(> 1980)
285 9.8 16.5 0.55 
(0.22–1.37)
0.201 0.58 
(0.23–1.46)
0.250 0.59 (0.23–1.49) 0.260
gynaecological 
surgery1
63 50.0 69.2 0.44 
(0.16–1.27)
0.130 0.43 
(0.15–1.25)
0.121 0.48 (0.16–1.45) 0.194
gynaecological 
surgery (> 
1980)1
63 25.0 33.3 0.67 
(0.21–2.08)
0.485 0.57 
(0.17–1.94)
0.371 0.77 (0.21–2.80) 0.694
orthopaedic 
surgery
293 52.2 20.5 4.22 
(2.38–7.49)
0.000 4.41 
(2.47–7.89)
0.000 4.77 (2.60–8.83) 0.000
orthopaedic 
surgery (> 1980)
293 44.9 20.1 3.25 
(1.82–5.77)
0.000 3.39 
(1.89–6.08)
0.000 3.55 (1.94–6.49) 0.000
tonsillectomy 292 35.3 36.6 0.94 
(0.54–1.66)
0.844 0.93 
(0.53–1.65)
0.806 1.04 (0.58–1.88) 0.889
tonsillectomy 
(> 1980)
292 2.9 23.7 0.10 
(0.02–0.41)
0.002 0.10 
(0.02–0.40)
0.001 0.05 (0.01–0.36) 0.003
organ 
transplantation
292 1.5 0.5 3.33 
(0.21–53.93)
0.397 3.36 
(0.20–55.81)
0.398 2.69 
(0.16–45.67)
0.494
1) female subjects, GP controls onlyPage 7 of 12
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appendectomy (OR: 0.476; 95% CI 0.24–0.94) and lum-
bar puncture (OR: 0.261; 95% CI 0.10–0.65), to have ever
smoked (OR: 0.269; 95% CI 0.12–0.62), to own a pet
rodent (OR: 0.220; 95% CI 0.11–0.46).
Discussion
This study evaluated a wide range of possible risk factors
as risk factors for sCJD-cases observed in Switzerland
between 2001 and 2004. If some of the positively associ-
ated risk factors were truly causal and would have become
more frequent in recent years and decades, then they
might have contributed to the increase in sCJD-cases in
Switzerland. Although some analysed factors were signifi-
cantly more frequent in the group of sCJD patients, the
results of this case-control study have not produced une-
quivocal evidence for specific environmental or iatrogenic
risk factors for sCJD, and thus could not reveal a specific
explanation for the increased incidence. In interpreting
the results, one has to bear in mind that with a signifi-
cance level set at 5%, on average one in twenty results will
be significant, by chance alone.
Table 4: Medical risk factors – medication, allergies, invasive procedures, injections, blood transfusions, cigarettes and illegal drugs
comparison with all control subjects
risk factor n total mean (SD) or % crude estimate age and sex adjusted 
estimate
age, sex and education 
adjusted estimate
cases n = 69 controls
n = 224
OR (95% CI) p OR (95% CI) p OR (95% CI) p
regular GP 
visits1
292 61.8 20.1 6.43 
(3.57–11.57)
0.000 6.44 
(3.57–11.62)
0.000 6.33 
(3.44–11.64)
0.000
regular 
medication
291 86.6 75.9 2.05 
(0.95–4.40)
0.067 2.30 
(1.05–5.05)
0.037 2.30 (1.04–5.10) 0.040
hormones, ever 292 14.7 22.3 0.60 
(0.29–1.26)
0.177 0.66 
(0.29–1.50)
0.319 0.67 (0.28–1.61) 0.366
allergies2 135 9.1 14.5 0.59 
(0.20–1.73)
0.336 0.66 
(0.22–2.05)
0.477 0.59 (0.18–1.95) 0.383
visit to a 
urologist3
171 32.6 39.8 0.73 
(0.35–1.51)
0.395 0.75 
(0.35–1.58)
0.447 0.79 (0.36–1.74) 0.559
visit to a 
psychiatrist
292 14.7 12.5 1.21 
(0.55–2.63)
0.636 1.16 
(0.53–2.58)
0.707 1.33 (0.57–3.12) 0.509
contact lenses 291 1.5 4.5 0.32 
(0.04–2.58)
0.287 0.37 
(0.05–3.02)
0.355 0.47 (0.06–3.86) 0.482
regular 
injections
290 16.7 23.2 0.66 
(0.32–1.36)
0.259 0.68 
(0.33–1.39)
0.285 0.65 (0.31–1.37) 0.256
vaccinations 
(> 1980)
288 64.1 63.0 1.05 
(0.59–1.87)
0.870 1.03 
(0.58–1.85)
0.915 1.10 (0.61–2.00) 0.753
acupuncture, 
ever
290 13.6 21.9 0.56 
(0.26–1.22)
0.145 0.57 
(0.26–1.26)
0.167 0.60 (0.27–1.34) 0.211
lumbar 
puncture, ever
289 10.8 25.5 0.35 
(0.15–0.82)
0.015 0.34 
(0.15–0.80)
0.013 0.32 (0.13–0.79) 0.013
blood 
transfusions
291 22.4 26.8 0.79 
(0.41–1.50)
0.471 0.83 
(0.43–1.58)
0.563 0.81 (0.41–1.56) 0.522
blood 
transfusions 
(> 1980)
291 6.0 11.6 0.48 
(0.16–1.44)
0.191 0.52 
(0.17–1.55)
0.240 0.51 (0.17–1.54) 0.231
blood donation 290 16.7 47.8 0.22 
(0.11–0.44)
0.000 0.16 
(0.07–0.33)
0.000 0.16 (0.07–0.34) 0.000
invasive dental 
treatment 
(> 1980)
290 78.8 62.5 2.23 
(1.16–4.27)
0.016 2.25 
(1.17–4.32)
0.015 2.63 (1.33–5.19) 0.006
tattoo's 290 1.5 1.8 0.85 
(0.09–7.70)
0.882 0.91 
(0.10–8.34)
0.933 0.87 (0.09–8.14) 0.906
piercings/
earrings
290 13.4 19.6 0.63 
(0.29–1.38)
0.251 0.73 
(0.30–1.78)
0.483 0.73 (0.29–1.83) 0.503
current 
cigarette 
smoker
284 13.3 29.0 0.38 
(0.17–0.84)
0.016 0.34 
(0.15–0.76)
0.009 0.34 (0.15–0.78) 0.010
illegal drugs 289 1.5 4.5 0.33 
(0.04–2.66)
0.301 0.32 
(0.04–2.53)
0.278 0.37 (0.05–3.04) 0.355
1) other than for CJD 2) GP controls only 3) male subjects onlyPage 8 of 12
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the development of vCJD by consumption of BSE-con-
taminated material, the present study does not demon-
strate a clearly increased risk for sCJD with respect to
dietary habits. Although previous studies revealed that
consumption of several meat products was increased in
sCJD cases compared to controls,[26,27] no such clear dif-
ferences for any of the twenty diet-related exposures were
found in our as well as in earlier studies. [28-30] Consist-
ent with previous studies, no significant differences
between sCJD patients and controls was found with
respect to occupational exposures, including work in ani-
mal farming or in the meat industry in the present study.
One exception was work in an animal laboratory. [27-31]
Some findings of earlier studies which revealed higher fre-
quencies of sCJD among butchers,[32] among those
exposed to leather products, to fertiliser consisting of
hoofs and horns,[27] and to farm-stays for any length of
time,[31] could not be reproduced in this study. Contrary
to the hypothesis of a zoonotic cause, earlier studies did
not link pet animals possession to increased risk. [27-30]
Patients in this study even less often owned cats or pet
rodents. Travelling abroad was significantly more fre-
quent in sCJD patients. Controls, however, travelled more
frequently to the United Kingdom where risk for vCJD
was elevated and to tropical destinations where some
Table 5: Dietary risk factors – food habits: meat, innards and dairy products (> 1980)
comparison with all control subjects
Risk factor n
total
mean (SD) or % crude estimate age and sex adjusted 
estimate
age, sex and education 
adjusted estimate
cases n = 69 controls n = 
224
OR (95% CI) p OR (95% CI) p OR (95% CI) p
vegetarian for 
> 1 year
290 3.0 5.4 0.55 
(0.12–2.53)
0.445 0.62 
(0.13–2.93)
0.550 0.81 
(0.17–3.95)
0.798
cow's milk 
(regularly/daily)
288 87.7 87.9 0.98 
(0.43–2.28)
0.965 0.98 
(0.42–2.30)
0.962 1.00 
(0.42–2.39)
0.997
cheese 
(> 1/week)
288 95.4 96.0 0.87 
(0.23–3.31)
0.837 0.84 
(0.22–3.22)
0.800 0.68 
(0.17–2.71)
0.588
beef (> 1/week) 287 50.8 54.5 0.86 
(0.49–1.50)
0.595 0.84 
(0.48–1.47)
0.549 0.88 
(0.50–1.55)
0.650
veal (> 1/week) 286 40.6 30.6 1.55 
(0.87–2.75)
0.135 1.51 
(0.84–2.69)
0.167 1.55 
(0.86–2.80)
0.142
pork 
(> 1/week)
287 63.1 62.6 1.02 
(0.58–1.81)
0.946 0.99 
(0.55–1.76)
0.960 0.93 
(0.52–1.68)
0.811
lamb, ever 287 81.5 86.0 0.72 
(0.34–1.49)
0.373 0.63 
(0.29–1.34)
0.229 0.74 
(0.34–1.64)
0.463
game/venison, 
ever
285 87.5 81.5 1.59 
(0.71–3.60)
0.262 1.45 
(0.63–3.35)
0.384 1.48 
(0.64–3.45)
0.362
chicken 
(> 1/week)
285 63.5 57.7 1.28 
(0.73–2.33)
0.407 1.28 
(0.71–2.28)
0.411 1.23 
(0.68–2.21)
0.495
sausages 
(> 1/week)
283 54.1 42.8 1.58 
(0.89–2.78)
0.118 1.51 
(0.85–2.69)
0.161 1.55 
(0.86–2.78)
0.147
hamburgers at 
restaurants, 
ever
286 37.5 24.8 1.82 
(1.01–3.29)
0.047 1.76 
(0.95–3.24)
0.070 1.74 
(0.93–3.26)
0.086
innards, ever 287 56.9 50.5 1.30 
(0.74–2.27)
0.359 1.27 
(0.72–2.23)
0.404 1.32 
(0.75–2.35)
0.337
liver, ever 287 78.5 73.9 1.29 
(0.66–2.50)
0.454 1.28 
(0.66–2.49)
0.469 1.23 
(0.62–2.47)
0.552
kidneys, ever 287 33.9 22.5 1.76 
(0.96–3.22)
0.066 1.68 
(0.91–3.09)
0.094 1.96 
(1.04–3.68)
0.037
liver sausage/
paté, ever
285 66.7 62.6 1.19 
(0.66–2.15)
0.556 1.16 
(0.64–2.11)
0.620 1.16 
(0.64–2.13)
0.626
blood sausage/
black pudding, 
ever
285 57.1 54.1 1.13 
(0.64–1.99)
0.664 1.11 
(0.63–1.95)
0.729 1.12 
(0.63–2.00)
0.696
tartare/
carpaccio, ever
286 31.3 36.0 0.81 
(0.44–1.46)
0.480 0.75 
(0.41–1.38)
0.362 0.84 
(0.45–1.56)
0.585
brain, ever 287 4.6 9.9 0.44 
(0.13–1.52)
0.194 0.42 
(0.12–1.47)
0.177 0.51 
(0.14–1.79)
0.290
eyes, ever 287 1.5 0.5 3.45 
(0.21–55.99)
0.383 3.00 
(0.18–49.06)
0.441 5.59 
(0.33–96.89)
0.235
cat-food, ever 290 0.0 1.3 -- -- -- -- -- --Page 9 of 12
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land. No differences in age, sex, place of birth and living
or family history of dementia were found. These results
are consistent with data from previous studies.[26,28,29]
In contrast to earlier studies, sCJD-patients in our study
had completed less years of education.[26,28] Only 45%
of the cases had ten or more school years, whereas this fig-
ure was at 71% among the controls. These findings might
be due to recall bias which can occur when interviewing
proxy persons. However, another neurodegenerative dis-
ease, Alzheimer's disease has been shown to be observed
more frequently in persons with lower levels of educa-
tion.[33]
Concerning the hypothesis of an iatrogenic cause, sCJD
cases in this study significantly more often had undergone
orthopaedic and ophthalmologic surgery, invasive dental
treatment as well as regular medical treatment. In previ-
ous studies, physical injuries and stressful life events such
as surgical procedures,[23,28,30,31,34,35] and work in a
medical profession[32] have been found to constitute a
risk factor for sCJD. In particular, head surgery and trauma
to other body parts were identified.[36] In contrast to the
present study, however, orthopaedic surgery and invasive
dental treatments per se were not associated with an ele-
vated risk for sCJD before.[27,28,31,36] One could spec-
ulate that the use of surgical instruments as well as a
potentially higher rate of blood transfusions in orthopae-
dic surgery may explain these findings. Receiving blood
transfusions has been demonstrated to be a potential
route of vCJD transmission.[20] The development of
vCJD involves a peripheral route of prion transmission to
the CNS. In sCJD, however, the disease most likely starts
in the brain, even though recently, prions have been
detected in peripheral organs such as the spleen and skel-
etal muscles of sCJD patients.[37] Blood transfusions,
however, were not associated with sCJD in the present
study. Interestingly, blood donation was less frequently
observed in sCJD patients than in controls. Correspond-
ingly, neither receiving blood transfusions nor blood
donation was identified as a risk factor for sCJD in previ-
ous studies.[23,26,38,39] Cigarette smoking was more
frequent in controls (29%) than in sCJD patients (13%)
or in the general population, a finding which points to
some bias in the selection of controls. A previous analysis
did not find any association with smoking.[26]
Recently, the heightened incidence of sCJD in Switzerland
was found to be associated with a shift in clinicopatholog-
ical profiles, in that sporadic CJD patients from the cohort
with elevated sporadic CJD incidence presented with a
higher frequency of rare sporadic CJD-subtypes (MV2,
VV2). Patients of these subtypes were significantly older
and showed a skewed male/female ratio when compared
to patients of identical sporadic CJD-types or to patients
from the 1996–2000 cohort.[22]
The third hypothesis to explain the increase in annual
mortality rates from sCJD in Switzerland between 2001
and 2004 is a better case ascertainment. Over recent years
in Europe, as a general tendency incidences have been ris-
ing, however not to such extent as in Switzerland. Given
that our results do not support strong evidence for the
hypotheses of a zoonotic or iatrogenic cause, ascertain-
ment bias due to a heightened perception and awareness
of the disease in physicians must be regarded as the most
likely cause for the observed increase. One factor that
might be jointly responsible for this increase might be
altered reporting requirements in 1999. Since that year all
suspected cases in Switzerland had to be reported. In this
respect, also the role of chance must be considered, as it is
possible that the observed increase of Swiss sCJD-deaths
was due to random fluctuation. The rise in annual mortal-
ity rate from the years before 2000 to the period 2001–
2004, however, was statistically significant, and therefore,
chance must be considered a less likely explanation. In the
most recent years, the observed incidence in sCJD deaths
(2005: 10; 2006: 13, 2007: 15) dropped to levels just
slightly above those before 2000. When recent incidence
data until 2007 are included, however, the rise in the
annual mortality rate after 2001 was still significant. The
sudden increase in 2001 and the slow decrease afterwards
are well in line with the media coverage of the CJD topic
in the respective years.
Strengths and limitations
This study was initiated to clarify whether cases of sCJD
from 2001 to 2004 were associated with a specific envi-
ronmental risk factor in Switzerland. A well defined group
of patients was examined. The 69 sCJD cases consisted of
all but three known cases in Switzerland during the study
period. The participation rate of relatives and friends of
cases was high, and for cases and controls there were only
few missing data points in the data sets. The study used a
standardised questionnaire with a wide range of potential
risk factors reported in previous studies. However a sub-
type analysis in correlation with risk factors was not per-
formed in this analysis because of the small number of
cases.
Due to Switzerland's small population size, the rarity of
the disease, and the fact that sCJD invariably leads to
death within less than 2 years, the number of cases in the
study was relatively small. Other case-control studies con-
ducted in Europe were somewhat larger. However, of
these studies, just four recent studies also included data of
cases from the year 2001 or later,[32,40-42] and none was
performed within Switzerland. Consequently, they could
not contribute to an explanation for the increased inci-
dence of reported sCJD deaths in Switzerland. Two differ-
ent control groups were chosen to limit selection bias. The
interviews of controls by telephone yield potential for
self-selection bias in that ownership of a fixed telephonePage 10 of 12
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tributed among the general population. On the other
hand, the control-group of patients from GP offices were
matched more closely but certain illnesses and other fac-
tors may be overrepresented in this group. The inter-
viewed control persons answered the questions directly –
either by a face-to-face interview or by telephone, whereas
for the cases a close relative or friend of the patient
answered the questions as a proxy. Furthermore, inter-
viewed persons were conscious about the aims of the
study, all of which could have resulted in the introduction
of recall bias. Interviewing a proxy person for sCJD cases
could imply that responses were less accurate, with fewer
positive responses with respect to potential risk factors,
potentially masking differences between the cases and
controls. Conversely, a face-to-face interview could have
resulted in more accurate data than a telephone interview.
For instance, in the subgroup analysis comparing oph-
thalmologic surgery after 1980 in patients and telephone
controls, the finding of an odds ratio of 18.31 with a very
wide 95% C.I. of 3.65–91.97 has to be interpreted with
care. Only 2 of 155 telephone controls (1.3%) recalled
having undergone ophthalmologic surgery after 1980,
while in the face-to-face interviews this proportion was
15.4% among proxy persons for patients and 24.6%
among the GP controls. In the present study, we
renounced interviewing proxy persons for controls, since
we hypothesised that proxy-persons for cases would be
more disposed to answer such questions correctly than
proxy-persons for controls would do, and that such an
effort would not have excluded recall bias.
Unanswered questions, future research
To identify environmental or other causes of sCJD, further
research is necessary. The questionnaire of our study has
been used in other CJD case-control studies,[23,24] which
will allow to combine our results with those from other
studies. As a potential risk factor for prion infection, ear,
nose and throat (ENT) – surgery was not included as an
item in this study. Other than recall bias, we could not
find an explanation, why some of the examined factors,
such as the number of school years differed between sCJD
cases and controls.
In this study, no genetic markers were analysed. For prac-
tical and ethical reasons, this information was only avail-
able for patients and not for controls. However, such
information could have given additional clues, in that the
development of sporadic CJD due to environmental fac-
tors might be linked to some so far unknown genetic fac-
tors. More recent research indicates that there are different
subtypes of sCJD. Patients have a wide range of genetic
backgrounds, which results in different clinical and his-
topathological presentations and diverse PrPSc distribu-
tion patterns in the brain.[43]
Conclusion
This study did not reveal a specific explanation for the
increased annual death rates for sCJD observed in Switzer-
land between 2001 and 2004 with respect to external –
and potentially avoidable – risk factors. Although some
factors were significantly more frequent in the group of
sCJD cases, the results have to be interpreted with caution
due to fact of having tested multiple hypotheses and due
to the possibility of bias in the selection of controls and of
recall bias in association with the potentially long incuba-
tion period as seen in other prion diseases. The most plau-
sible reason for the observed increase in 2001 in Swiss
sCJD cases is an improved case ascertainment. The
improved reporting of cases was in temporal correlation
with the rise in variant CJD cases in the United Kingdom
and the resulting high media coverage. Therefore, under-
reporting of cases might well have occurred before the
year 2001, and the "real" yearly incidence of sCJD might
not be lower than, but rather above 2 per million inhabit-
ants.
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